- Mar 27
- |
- 2025

Press Release
We leverage 5 key platforms to deliver groundbreaking proteomic services. The HuProt™ Human Proteome Microarray offers the most extensive collection of full-length, folded proteins available for whole proteome assays. Our PhIP-Seq platforms, HuScan®, MouseScan™ and VirScan®, enable epitope-level profiling against human and mouse proteomes, as well as most vertebrate viral proteomes. The VirD™ Functional Membrane Protein Microarray offers the capability to assay membrane-embedded functional proteins in a highly multiplexed format.
* Provided exclusively by CDI Labs Canada.
Autoantibody seromics is the study of the autoantibody reactome, a complex network of interactions and effects driven by autoantibodies that mistakenly target the body’s own tissues. Autoantibodies can arise from inflammation, infections, or tissue damage, and play critical roles in autoimmune and non-autoimmune conditions, including neurological disorders, cancer, infectious diseases, genetic disorders, and cardiovascular issues. Our services enable proteome-wide autoantibody profiling with the HuProt™ Human Proteome Microarray, to assay binding to full-length folded proteins, and PhIP-Seq-based services such as HuScan® and MouseScan™ PhIP-Seq to assay epitope-level binding.
Target identification is a vital step in drug discovery and development, focusing on pinpointing specific molecules or biological pathways critical to a disease process and suitable for therapeutic intervention. The HuProt™ Human Proteome Microarray and VirD™ Functional Membrane Protein Microarray are advanced tools for Target ID studies. HuProt enables researchers to analyze compound interactions with full-length, folded, human proteins at a proteome-wide scale, while VirD enables highly-multiplexed analysis of binding to membrane-embedded proteins.
We leverage cutting-edge synthetic biology platforms and an extensive proteome collection to provide specialized, tailored services. Supported by a team of experts, we empower clients to uncover molecular interactions across entire proteomes. Committed to fostering strong partnerships, we aim to be a reliable ally in helping clients achieve their scientific and commercial goals.
We focus on advancing research in autoimmune diseases, neurological diseases, oncology, infectious diseases, genetic diseases and the study of aging with our cutting-edge services for proteome-wide autoantibody profiling and target identification. Our products, including the HuProt™ Human Proteome Microarray, the VirD™ Functional Membrane Protein Microarray, and PhIP-Seq-based services like VirScan®, HuScan®, and MouseScan™, empower researchers and drug developers to achieve breakthroughs across a wide spectrum of scientific fields.
Correctly-folded, GST-purified recombinant proteins and isoform variants
Detects antibodies against 48,921 unique human proteins and protein isoforms
Detects antibodies against 50,135 unique murine proteins and protein isoforms
VirScan, HuScan and MouseScan are provided exclusively by CDI Labs Canada.
Contains over
21,000+
human proteins and isoform variants
Covers
16,794
unique genes
Contains over
81%
of human proteins in each major category
Covers
15,889
of 19,613 canonical human proteins described in Human Protein Atlas
Published in over
270+
high-profile publications
Sensory neuronopathies (SNN) encompass diverse etiologies, with autoimmunity playing a major role through both cellular and humoral responses. To investigate the humoral autoantibody repertoire in autoimmune SNN, we conducted a retrospective cohort study using large Human Proteome-wide protein microarrays (HuProt 3.1, HuProt 4.0, ProtoArrays). We specifically analyzed immune system pathways targeted within the autoantigen repertoire (the autoantigenome). We included 131 participants: 44 patients with non-paraneoplastic autoimmune SNN (12 with anti-FGFR3 and/or anti-AGO antibodies), 8 with paraneoplastic SNN, and 79 controls. Findings were validated in an independent cohort of 16 SNN patients. Overrepresentation of immune-system-related proteins was assessed using the Reactome database, and serum levels of IFN-γ and IL-6 were measured with the Bio-Plex Pro™ Reagent Kit. Autoimmune SNN sera interact with significantly more immune system proteins than healthy controls (ProtoArrays: 271/863 vs. 14/863, HuProt: 112/1694 vs. 39/1694, both p < 0.0001). Overrepresentation was observed across all major immune sub-pathways, including innate and adaptive immune responses as well as cytokine signaling. Anti-FGFR3-positive SNN patients showed more frequent reactivity to immune system proteins than anti-FGFR3-negative ones. The independent SNN cohort validated the overrepresentation of targeted immune system pathways. Validation with dot blot and ELISA confirmed reactivity to TRIM21 and IL-6 and identified anti-IFN-γ-positive SNN patients. IFN-γ levels correlated weakly with levels of anti-IFN-γ antibodies (Pearson's r = 0.22, p = 0.03). We conclude that the antibody repertoire of autoimmune SNN targets pathways of the innate and adaptive immune system, potentially reflecting key disease-related immune pathways and highlighting the systemic role of immune dysregulation in SNN.
We start with sequence-confirmed plasmids, then individually express and GST-purify proteins from S. cerevisiae. Piezolelectric inkjet printing is used to spot these in duplicate alongside controls. Quality is confirmed with anti-GST QA/QC. Successful folding demonstrated by kinase autophosphorylation assay.
With over 270 publications (and growing), our antibody seromics solutions, HuProt microarray and PhIP-Seq continue to play a key role in life sciences by contributing to critical studies that help accelerate research, advance discoveries, and translate discoveries to novel products that improve human health.
Our customer base continues to expand throughout North America, Europe, and Asia Pacific, and is a testament to the quality and consistency of our products and services.
Funded by NIH Common Fund Support for the Development of Protein Capture Reagents and Technologies, the HuProt Protein Microarray was created by CDI Labs co-founders Jef Boeke, Heng Zhu, Dan Eichinger, and Seth Blackshaw, faculty members at the High Throughput Biology (HIT) Center at the Johns Hopkins University School of Medicine.